Brief: Briacell Reports Outperforming Metastatic Breast Cancer Patients And Standard-Beating Survival Data
22/10/2024 13:13
Oct 22 (Reuters) - Briacell Therapeutics Corp BCT.TO :
* BRIACELL REPORTS OUTPERFORMING METASTATIC BREAST CANCER
PATIENTS
AND STANDARD-BEATING SURVIVAL DATA
* BRIACELL THERAPEUTICS CORP - MULTIPLE BRIACELL PATIENTS
SHOW
OVER 2 YEARS SURVIVAL
* BRIACELL THERAPEUTICS CORP - NO BRIACELL-IMT RELATED
DISCONTINUATIONS REPORTED
Source text for Eikon: ID:nGNX4RfqCx
Further company coverage: BCT.TO
((Reuters.Briefs@thomsonreuters.com))
Recent news on Briacell Therapeutics
See all newsBrief: Briacell Therapeutics Prices 1.45 Million Common Shares At $3.25 Per Share
Brief: Briacell Receives Positive Recommendation From Data Safety Monitoring Board (Dsmb) For Phase 3 Study In Metastatic Breast Cancer
Brief: Briacell Expands Pipeline To Include An Ovarian Cancer Immunotherapy Candidate, Bria-Ova+™
Brief: Briacell Phase 3 Bria-Imt™ Study Enrollment Surpasses 230 Patients
Brief: Briacell Adds Nyu Langone Health’S Perlmutter Cancer Center As Clinical Site In Pivotal Phase 3 Breast Cancer Study